TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35775390
Drug: CD34 cell
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34 cell therapy
Study: 35776185
Drug: Doxycycline 50
Normalized name: doxycycline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 50 mg once daily
Study: 35776185
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg once daily
Study: 35776269
Drug: SB5-HC (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB5-HC (40 mg/0.4 ml)
Study: 35776269
Drug: SB5-LC (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB5-LC (40 mg/0.8 ml)
Study: 35776489
Drug: Daily meditation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily meditation via Calm app
Study: 35777186
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg Q3W for up to 35 cycles (∼2 years)
Study: 35777697
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy (MET) 'check-ups'
Study: 35778568
Drug: Selective agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective agonist of CB2r (JWH133)
Study: 35778674
Drug: Preoperative frailty
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative frailty domains (medication use, living situation, mobility, gait speed, Nagi's physical functioning, preoperative HRQL)
Study: 35779095
Drug: Polyvalent antigen-KLH
Normalized name: Polyvalent antigen-KLH conjugate vaccine
DrugBank: Polyvalent antigen-KLH conjugate vaccine (DB17565)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvalent antigen-KLH plus OPT-821 vaccine construct and bevacizumab
Study: 35779659
Drug: TXR 140
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXR 140 μg
Study: 35779659
Drug: TXR 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXR 200 μg
Study: 35780092
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion in SOMATO-treated patients
Study: 35780092
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion in SOMATO-untreated patients
Study: 35780095
Drug: ePRO follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: ePRO follow-up pathway with automated 3-monthly reminders for ePRO questionnaire and blood tests.
Study: 35780243
Drug: Troriluzole (BHV-4157)
Normalized name: Troriluzole
DrugBank: Troriluzole (DB15079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troriluzole (BHV-4157) 420 mg total daily dose in combination with nivolumab 240 mg IV every 2 weeks
Study: 35780243
Drug: Troriluzole monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troriluzole monotherapy (lead-in period)
Study: 35782623
Drug: Oral lucerastat
Normalized name: Lucerastat
DrugBank: Lucerastat (DB14872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lucerastat twice daily for 6 months
Study: 35782751
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m2)
Study: 35782954
Drug: Prebiotic fiber
Normalized name: Benefiber Prebiotic Fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic fiber supplement (12 g daily)
Study: 35782954
Drug: Placebo (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 g daily)
Study: 35783822
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg po twice daily for 30 days plus standard of care
Study: 35784017
Drug: Paracetamol and
Normalized name: Paracetamol and tramadol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol and opioids
Study: 35784545
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone sensitivity (measured by TSHI, TFQI, TSHI, TT4RI, PTFQI, FT3/FT4)
Study: 35784545
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone sensitivity (in females)
Study: 35784545
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone sensitivity (in patients aged over 60 years)
Study: 35784641
Drug: Adipose-derived MSC
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose-derived MSC infusions (1 × 10)
Study: 35785613
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support services integrated into primary care for OUD treatment.
Study: 35785613
Drug: Buprenorphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine treatment for OUD.
Study: 35786544
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ACC and PPG modalities
Study: 35787784
Drug: PI3Kα inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PI3Kα inhibitor alpelisib
Study: 35787831
Drug: edoxaban (3-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: edoxaban (3-month treatment)
Study: 35788722
Drug: Niraparib 200
Normalized name: niraparib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 200 mg once daily in 28-day cycles
Study: 35789068
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (most common treatment regimen, 24.8%)
Study: 35789261
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) therapy during late pregnancy
Study: 35789594
Drug: JOTROL (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: JOTROL (a highly bioavailable resveratrol preparation)
Study: 35790143
Drug: Blinatumomab (9-28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab (9-28 μg/day for adults; 5-15 μg/m2/day for pediatrics)
Study: 35790315
Drug: Ceralasertib (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceralasertib (240 mg two times a day) plus durvalumab (1500 mg) every 4 weeks
Study: 35790332
Drug: Neotree e-health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neotree e-health solution (android app with data visualisation)
Study: 35790651
Drug: Antifibrotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifibrotic therapy (specifics not provided)
Study: 35791625
Drug: semaglutide 2.4
Normalized name: semaglutide 2.4 MG in 0.75 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide 2.4 mg single-dose pen-injector
Study: 35792924
Drug: PegaGen (pegfilgrastim)
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PegaGen (pegfilgrastim) administered once per cycle, with a single 6 mg dose injected in 99.17% of cycles.
Study: 35793925
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HPV E4 and p16
Study: 35793990
Drug: DA-8010 5
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-8010 5 mg
Study: 35793990
Drug: DA-8010 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-8010 2.5 mg
Study: 35794343
Drug: BACE inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: BACE inhibitor verubecestat
Study: 35794614
Drug: Regional anesthesia
Normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional anesthesia techniques (specifically double injection erector spinae plane block)
Study: 35794614
Drug: Double injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double injection erector spinae plane block
Study: 35794623
Drug: Nintedanib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 200 mg bid in combination with pembrolizumab 200 mg Q3W
Study: 35794623
Drug: Nintedanib 150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 150 mg bid in combination with pembrolizumab 200 mg Q3W
Study: 35794623
Drug: Nintedanib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 200 mg bid
Study: 35794623
Drug: Nintedanib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib and pembrolizumab therapy
Study: 35795231
Drug: Italian version
Normalized name: ALLERGENIC EXTRACT, ITALIAN RYEGRASS POLLEN
DrugBank: Lolium perenne subsp. multiflorum pollen (DB10964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Italian version of the LARS score (tested twice)
Study: 35795367
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment of CSA)
Study: 39307144
Drug: Rodatristat ethyl
Normalized name: Rodatristat ethyl
DrugBank: Rodatristat ethyl (DB18479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rodatristat ethyl 300 mg twice daily
Study: 39307144
Drug: Rodatristat ethyl
Normalized name: Rodatristat ethyl
DrugBank: Rodatristat ethyl (DB18479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rodatristat ethyl 600 mg twice daily
Study: 35795629
Drug: 3D Virtual
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D Virtual Reality training for chemotherapy administration
Study: 35795849
Drug: Intraovarian injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAOVARIAN LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraovarian injection of platelet-rich plasma (PRP) (1.5 ml) with an average of 12 injections per ovary.
Study: 35796785
Drug: Bendamustine hydrochloride
Normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine hydrochloride (10-min dosing)
Study: 35796785
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m
Study: 35797012
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy with pertuzumab (840 mg first cycle, 420 mg subsequent cycles), atezolizumab (1200 mg), docetaxel (75 mg/m2), and trastuzumab (600 mg subcutaneous) every 3 weeks for 6 cycles.
Study: 35797012
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy for patients with pCR: 12 cycles of atezolizumab, trastuzumab, and pertuzumab every 3 weeks after surgery.
Study: 35797012
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy for patients without pCR: 14 cycles of atezolizumab (1200 mg) plus trastuzumab emtansine (3.6 mg/kg) every 3 weeks.
Study: 35797012
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (overall treatment)
Study: 35797864
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) treatment
Study: 35798000
Drug: Homologous mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homologous mRNA vaccine boosting
Study: 35798000
Drug: Heterologous mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterologous mRNA and Ad26.COV2.S vaccine boosting
Study: 35798241
Drug: SH-1028 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SH-1028 (200 mg/d orally until disease progression or intolerable toxicity)
Study: 35798468
Drug: S-1-based treatment
Normalized name: S-38093 free base
DrugBank: S-38093 (DB16893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1-based treatment after cardiotoxicity from capecitabine or 5-FU
Study: 35798468
Drug: S-1-based treatment
Normalized name: S-38093 free base
DrugBank: S-38093 (DB16893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1-based treatment
Study: 35799116
Drug: Elevated serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated serum thyroid-stimulation hormone (TSH) levels
Study: 35799290
Drug: SABA prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: SABA prescription (≥3 canisters)
Study: 35799290
Drug: SABA prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: SABA prescription (≥10 canisters)
Study: 35799290
Drug: SABA prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: SABA prescription and OTC purchase
Study: 35799394
Drug: Selpercatinib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selpercatinib (160 mg bid, orally, 28-day cycles)
Study: 35800017
Drug: Integrated Social
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Social Cognitive and Behavioral Skill Therapy (ISST)
Study: 35800360
Drug: Intracoronary reteplase
Normalized name: reteplase
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary reteplase (9 mg or 18 mg)
Study: 35800670
Drug: Two tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of tramadol 37.5 mg/acetaminophen 325 mg ER FDC (DW-0920)
Study: 35800670
Drug: One tablet
Normalized name: Hydone Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of tramadol 75 mg/acetaminophen 650 mg
Study: 35801187
Drug: Alirocumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (150 mg every 2 weeks for 12 weeks)
Study: 35801558
Drug: Criterion-based, standardised,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Criterion-based, standardised, two-phase therapy protocol
Study: 35801762
Drug: Water-soluble contrast
Normalized name: WATER SOLUBLE BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-soluble contrast agent (iohexol) swallowing study (WSS)
Study: 35801795
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen at a flow rate of 2 L kg-1 min-1
Study: 35802001
Drug: Web-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based therapy (mixed-method cognitive behavioral therapy)
Study: 35802063
Drug: Sofosbuvir-velpatasvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir-velpatasvir (400 mg/100 mg) daily for 12 weeks
Study: 36967448
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant (DEX)
Study: 35802402
Drug: Friendship Bench
Normalized name: beach strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Friendship Bench (FB) program, a problem-solving therapy (PST)-based program adapted for use among people living with HIV on MMT.
Study: 35802405
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine U300 (IGlar-300)
Study: 35802405
Drug: Insulin Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin Degludec U100 (IDeg-100)
Study: 35802786
Drug: CPS-specific antibodies
Normalized name: methylcellulose (1500 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPS-specific antibodies
Study: 35802786
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of antibody levels
Study: 35803286
Drug: Mosunetuzumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosunetuzumab (1 mg on cycle 1 day 1, 2 mg on cycle 1 day 8, 60 mg on cycle 1 day 15 and cycle 2 day 1, 30 mg on day 1 of cycle 3 and onwards)
Study: 35803294
Drug: CEND-1 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEND-1 monotherapy
Study: 35803731
Drug: Woven EndoBridge
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Woven EndoBridge (WEB) device treatment
Study: 35803835
Drug: Olaparib treatment
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib treatment in gBRCAm cohort
Study: 35803835
Drug: Olaparib treatment
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib treatment in sBRCAm cohort
Study: 35803835
Drug: Olaparib treatment
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib treatment in HRD-positive cohort
Study: 35803835
Drug: Olaparib treatment
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib treatment in HRD-negative cohort
Study: 39361218
Drug: Radium-223 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radium-223 therapy
Study: 35804188
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who discontinued radium-223 therapy
Study: 35804294
Drug: Eptinezumab 300
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptinezumab 300 mg intravenous every 12 weeks for up to 8 doses
Study: 35804385
Drug: Bushen Culuan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen Culuan Decoction 13 g three times a day for 14 days and clomiphene citrate placebo tablets 50 mg once a day for 5 days starting on day 5 of every menstrual period.
Study: 35804385
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate tablets 50 mg once a day for 5 days starting on day 5 of every menstrual period (control group).
Study: 35804404
Drug: Topical sirolimus
Normalized name: sirolimus Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sirolimus solution (1 mg/mL) applied once daily for 24 weeks
Study: 35804454
Drug: Standard treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment: rifampicin plus clarithromycin for 8 weeks
Study: 35804454
Drug: Investigational treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational treatment: rifampicin plus clarithromycin plus amoxicillin/clavulanate for 4 weeks
Study: 35805716
Drug: Acute triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute triiodothyronine (T3) treatment
Study: 35805716
Drug: T3 administration
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T3 administration
Study: 35806269
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy with adjunctive systemic antibiotics (amoxicillin/metronidazole)
Study: 35808998
Drug: tDCS (transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDCS (transcranial direct current stimulation) combined with prolonged exposure (PE) therapy
Study: 35810079
Drug: Rescue subcutaneous
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue subcutaneous (s.c.) progesterone therapy (25 mg)
Study: 35810079
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone tablet plus i.m. progesterone (control group)
Study: 35810296
Drug: Sucroferric oxyhydroxide
Normalized name: Sucroferric Oxyhydroxide
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucroferric oxyhydroxide (SO) titrated to a goal serum phosphate of <5.5 mg/dL
Study: 35810553
Drug: Nazartinib 150
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nazartinib 150 mg once daily
Study: 35810555
Drug: Cyclic fasting-mimicking
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic fasting-mimicking diet (FMD) combined with standard anticancer therapies
Study: 35810555
Drug: Standard anticancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anticancer therapies
Study: 35812817
Drug: Elobixibat (EXB)
Normalized name: Exblifep
DrugBank: Elobixibat (DB12486)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Elobixibat (EXB) 10 mg/day for 4 weeks
Study: 35814366
Drug: AHCC 3-g
Normalized name: glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHCC 3-g supplementation by mouth once daily on empty stomach for 6 months
Study: 35814366
Drug: Suppression of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppression of IFN-β to less than 20 pg/ml
Study: 35815408
Drug: 9-ING-41, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-ING-41, a selective GSK-3β inhibitor
Study: 35815666
Drug: Standardized feminizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized feminizing hormone therapy (sFHT; oestradiol valerate 2-6 mg plus spironolactone 100-300 mg) plus PrEP for 12 weeks
Study: 35815666
Drug: Any feminizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any feminizing hormone therapy (aFHT) plus PrEP (long-term PK)
Study: 35816381
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical activity program including 3 types of exercises: staying out of bed for at least 3 hours, performing balance exercises while standing for 2 minutes, and the Five Times Sit to Stand transfer exercise.
Study: 35816381
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical activity program
Study: 35816411
Drug: ARCoV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARCoV vaccine
Study: 35816490
Drug: APN01 (soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: APN01 (soluble human recombinant ACE2) administered via nebulizer, twice daily for two weeks at maximum feasible concentration
Study: 35816831
Drug: Diazepam nasal
Normalized name: diazepam Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam nasal spray (Valtoco®)
Study: 35816942
Drug: Cyberknife System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyberknife System treatment plans based on unrotated volume
Study: 35816942
Drug: Cyberknife System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyberknife System treatment plans based on envelope of unrotated and rotated volumes
Study: 35816942
Drug: Gamma analysis
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma analysis of treatment plans
Study: 35816951
Drug: Retifanlimab 500
Normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retifanlimab 500 mg administered intravenously every 4 weeks
Study: 35818348
Drug: Oxaliplatin (OX)
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin (OX) treatment